15,000 Shares in Intra-Cellular Therapies Inc (NASDAQ:ITCI) Bought by Slow Capital Inc.

Slow Capital Inc. bought a new position in Intra-Cellular Therapies Inc (NASDAQ:ITCI) during the second quarter, according to the company in its most recent filing with the SEC. The firm bought 15,000 shares of the biopharmaceutical company’s stock, valued at approximately $195,000.

Other large investors have also modified their holdings of the company. BNP Paribas Arbitrage SA raised its position in Intra-Cellular Therapies by 883.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,361 shares of the biopharmaceutical company’s stock worth $126,000 after purchasing an additional 9,307 shares during the period. First Mercantile Trust Co. raised its position in Intra-Cellular Therapies by 12.3% in the 1st quarter. First Mercantile Trust Co. now owns 11,522 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 1,265 shares during the period. Metropolitan Life Insurance Co. NY raised its position in Intra-Cellular Therapies by 354.8% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,016 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 10,934 shares during the period. Legal & General Group Plc raised its position in Intra-Cellular Therapies by 9.4% in the 4th quarter. Legal & General Group Plc now owns 16,044 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 1,374 shares during the period. Finally, Aperio Group LLC raised its position in Intra-Cellular Therapies by 16.0% in the 2nd quarter. Aperio Group LLC now owns 17,206 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 2,367 shares during the period. Institutional investors own 69.45% of the company’s stock.

A number of equities analysts recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Intra-Cellular Therapies in a research report on Monday. They issued a “buy” rating and a $16.00 target price on the stock. Royal Bank of Canada set a $26.00 target price on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $29.00 target price (up previously from $26.00) on shares of Intra-Cellular Therapies in a research report on Thursday, May 23rd. BidaskClub cut shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 9th. Finally, Cowen reissued a “buy” rating and issued a $28.00 price target on shares of Intra-Cellular Therapies in a report on Monday, July 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. Intra-Cellular Therapies currently has a consensus rating of “Buy” and an average target price of $23.88.

Intra-Cellular Therapies stock traded down $0.21 during trading hours on Wednesday, reaching $9.04. The stock had a trading volume of 17,553 shares, compared to its average volume of 646,470. The stock has a market cap of $510.35 million, a PE ratio of -3.18 and a beta of 1.18. Intra-Cellular Therapies Inc has a 52 week low of $7.41 and a 52 week high of $23.62. The company has a current ratio of 8.86, a quick ratio of 8.86 and a debt-to-equity ratio of 0.08. The company’s fifty day simple moving average is $10.74.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.15. Research analysts predict that Intra-Cellular Therapies Inc will post -3.81 EPS for the current year.

In other news, Director Christopher D. Alafi purchased 170,000 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were acquired at an average price of $11.73 per share, with a total value of $1,994,100.00. Following the acquisition, the director now directly owns 750,106 shares in the company, valued at $8,798,743.38. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 18.20% of the stock is owned by company insiders.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.

Featured Story: What does an equal weight rating mean?

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.